Chimeric antigen receptor-T cell therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19-presentation on the cancer cells. To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B cell-specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR-T cell that simultaneously targets CD19 and CD22. In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T cell product quality.
Monday, September 27, 2021
2:30 - 3:30 PM Eastern Time
Meet the speaker
David Miklos, MD, PhD Chief, Blood and Marrow Transplantation and Cellular Therapy Clinical Director, Cancer Cell Therapy Stanford University
Sponsored by
Register Now
TS_Webinar_IsoPlexis_LabTools_Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies September 27, 2021_IO#402360
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
%20sept%2027%202.jpg?width=990&name=990x120%20(1)%20sept%2027%202.jpg "990x120 (1) sept 27 2")
